Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07685899 · ClinicalTrials.gov registry record · NA

Contingency Management to Promote Smoking Cessation: A Pilot Randomized Clinical Trial

A NA study, sponsored by University of Kansas Medical Center.

Not yet
Registry status
NA
Development phase
40
Enrollment target

NCT07685899: Clinical Trial NA study, sponsored by University of Kansas Medical Center.

NCT07685899 is a NA study that has not yet begun recruiting, run by University of Kansas Medical Center. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07685899, a NA study, has not yet begun recruiting, sponsored by University of Kansas Medical Center.

NOT YET RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

Adherence to medication and counseling are strong predictors of smoking cessation success. To provide these two components of care, healthcare providers typically provide people who smoke with prescriptions for cessation medications, and refer them to state-sponsored tobacco quitlines. However, most people who smoke that are referred to quitlines never actually enroll, and those who do enroll participate in very few sessions. Similarly, most people who smoke that receive prescriptions for cessation medications rarely fill or use them, even when they have no co-pay or pre-authorization requirements. To address this problem we will recruit 40 patients for a pilot 2-arm effectiveness trial. We will recruit patients from the University of Kansas Medical Center. Participants will then be randomized either to control or Health Reward. All participants will receive 12 weeks of varenicline and referrals to their state tobacco quitline (Control condition). In Health rewards arm, participants will additionally receive CM for medication (MedCM) and for counseling (CounsCM). The use of medication will be tracked using an electronic pill dispenser (Wisepill). All participants will be contacted for follow up 3, 6 and 12 weeks after starting the treatment. Feasibility data will include recruitment and retention rates. Preliminary effectiveness outcomes will include treatment engagement and cessation rates.

Primary Outcome

Feasibility endpoints include: (1) the proportion of eligible subjects who subsequently enroll; and (2) the proportion of enrolled subjects who complete the 3-week, 6-week, and 12-week assessments.

Interventions

  • BEHAVIORAL Control
  • BEHAVIORAL Health Rewards

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-08-20
Est. Completion 2027-05-30
Phase NA
University of Kansas Medical Center

408 total trials

What is known before NCT07685899 opens enrollment

NCT07685899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.

NCT07685899 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07685899 about?

NCT07685899 is a clinical study titled "Contingency Management to Promote Smoking Cessation: A Pilot Randomized Clinical Trial". Adherence to medication and counseling are strong predictors of smoking cessation success. To provide these two components of care, healthcare providers typically provide people who smoke with prescriptions for cessation medications, and refer them to state-sponsored tobacco quitlines. However, most...

What is the current status of trial NCT07685899?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-08-20. Estimated completion is 2027-05-30.

What interventions are being tested in trial NCT07685899?

The interventions under investigation include: Control (BEHAVIORAL), Health Rewards (BEHAVIORAL).

Who is sponsoring clinical trial NCT07685899?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07685899's enrollment target sits among peer trials

40 1447th of 2000 higher than 465 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07685899, the US trial registry maintained by the National Library of Medicine. NCT07685899 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.